Back Back
Expert Insights on HER2+ EBC
Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer: An Online Tool

Released: March 19, 2019

Expiration: March 17, 2020

Activity Information
Prev | Next

About This Tool

Clinical Care Options, LLC, is grateful to expert faculty Frankie Ann Holmes, MD, FACP; Sara Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; Mark D. Pegram, MD; and Denise A. Yardley, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: These data were compiled in October 2018 and include the opinions of the experts at that time.

The goal of this tool is to help you better understand your recent HER2-positive early breast cancer diagnosis and your initial treatment options to become partners with your oncology care team and not just a bystander in your cancer care.

A series of questions developed by the experts allow you to select information about yourself and your cancer that are necessary to consider when making treatment choices in early breast cancer. These characteristics include:

  • Type of treatment being considered (neoadjuvant or adjuvant)
  • Tumor size or stage
  • Lymph node status
  • Hormone receptor status
  • Menopausal status
  • Cardiac function and other treatment-related toxicities or comorbidities
  • Any previous systemic treatment history and your response to that treatment
  • Your primary goals for treatment outcome

If you do not have this information yet, you can ask your oncologist about these characteristics—sometimes it helps to have someone attend appointments with you to take notes or you can ask your oncologist if it is ok to record the conversation (most are fine with this and used to being recorded). We also developed a consultation checklist that you can print and take with you to your appointment to help you gather this information.

It should be noted that these factors are not the only things to consider when making management choices; other health issues (comorbidities) and disease characteristics that cannot be included in this tool also need to be considered and discussed with your oncologist to create the best plan for your individual needs.

Once your information is entered, you will also be asked to enter the treatment plan your care team has suggested. Select the answer option “I don’t know” if a plan has yet to be made. Afterward, you will see an Expert Insight table showing the treatment choices of all 5 experts based on the characteristics you entered. There may not be unanimous choice among the experts, which serves to show that there is typically more than one good option for a particular patient. This gives you and your team the opportunity to choose the best care for you.

You can print the expert choices along with a summary of the characteristics and selected therapy you entered by clicking Case Summary.

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

The “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool is designed to educate patients on optimal regimens for HER2+ early breast cancer, based on specific patient and disease characteristics. The information provided is based on the expert guidance of breast cancer experts Frankie Ann Holmes, MD, FACP; Sara Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; Mark D. Pegram, MD; and Denise A. Yardley, MD.

Although the information contained in the “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. Patients should always discuss their healthcare decisions with their oncology care team. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all data on the Clinical Care Options Web site including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Program Content